• Explore /
  • Poster
  • / In-depth analysis of responders in the phase 3 PhALLCON trial of ponatinib vs imatinib in newly diagnosed Ph+ ALL.

In-depth analysis of responders in the phase 3 PhALLCON trial of ponatinib vs imatinib in newly diagnosed Ph+ ALL.

Abstract Video & Slides Poster

Authors

null

Elias Jabbour

The University of Texas MD Anderson Cancer Center, Houston, TX

Elias Jabbour , Hagop M. Kantarjian , Ibrahim Aldoss , Pau Montesinos , Jessica Taft Leonard , David Gomez-Almaguer , Maria R. Baer , Carlo Gambacorti-Passerini , James K. McCloskey , Yosuke Minami , Cristina Papayannidis , Philippe Rousselot , Pankit Vachhani , Eunice S. Wang , Lin Yang , Meliessa Hennessy , Alexander Vorog , Niti Patel , Jose-Maria Ribera-Santasusana

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Track

Hematologic Malignancies

Sub Track

Acute Leukemia

Clinical Trial Registration Number

NCT03589326

Citation

J Clin Oncol 42, 2024 (suppl 16; abstr 6533)

DOI

10.1200/JCO.2024.42.16_suppl.6533

Abstract #

6533

Poster Bd #

92

Abstract Disclosures

Similar Posters

First Author: Elias Jabbour

First Author: Jeremy Chang

First Author: Nicholas James Short

First Author: Steven Bialick